

Wei Liu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5231756/publications.pdf>

Version: 2024-02-01

12
papers

1,751
citations

933264

10
h-index

1199470

12
g-index

15
all docs

15
docs citations

15
times ranked

3982
citing authors

#	ARTICLE	IF	CITATIONS
1	Proteomic and Metabolomic Characterization of COVID-19 Patient Sera. <i>Cell</i> , 2020, 182, 59-72.e15.	13.5	1,137
2	Multi-organ proteomic landscape of COVID-19 autopsies. <i>Cell</i> , 2021, 184, 775-791.e14.	13.5	272
3	A circulating extracellular vesicles-based novel screening tool for colorectal cancer revealed by shotgun and data-independent acquisition mass spectrometry. <i>Journal of Extracellular Vesicles</i> , 2020, 9, 1750202.	5.5	70
4	Proteomic and metabolomic profiling of urine uncovers immune responses in patients with COVID-19. <i>Cell Reports</i> , 2022, 38, 110271.	2.9	66
5	Quantitative Proteome Landscape of the NCI-60 Cancer Cell Lines. <i>IScience</i> , 2019, 21, 664-680.	1.9	52
6	DPHL: A DIA Pan-human Protein Mass Spectrometry Library for Robust Biomarker Discovery. <i>Genomics, Proteomics and Bioinformatics</i> , 2020, 18, 104-119.	3.0	51
7	Targeting P-Glycoprotein: Nelfinavir Reverses Adriamycin Resistance in K562/ADR Cells. <i>Cellular Physiology and Biochemistry</i> , 2018, 51, 1616-1631.	1.1	21
8	Computational Optimization of Spectral Library Size Improves DIA-MS Proteome Coverage and Applications to 15 Tumors. <i>Journal of Proteome Research</i> , 2021, 20, 5392-5401.	1.8	21
9	Combination of dihydromyricetin and ondansetron strengthens antiproliferative efficiency of adriamycin in K562/ADR through downregulation of SORCIN: A new strategy of inhibiting P-glycoprotein. <i>Journal of Cellular Physiology</i> , 2019, 234, 3685-3696.	2.0	19
10	Stratification of follicular thyroid tumours using data-independent acquisition proteomics and a comprehensive thyroid tissue spectral library. <i>Molecular Oncology</i> , 2022, 16, 1611-1624.	2.1	14
11	Proteomics profiling of colorectal cancer progression identifies PLOD2 as a potential therapeutic target. <i>Cancer Communications</i> , 2022, 42, 164-169.	3.7	7
12	DIA-Based Proteomics Identifies IDH2 as a Targetable Regulator of Acquired Drug Resistance in Chronic Myeloid Leukemia. <i>Molecular and Cellular Proteomics</i> , 2022, 21, 100187.	2.5	4